The modulation of Fasn by liver CRELD2 may play a crucial role in the dyslipidemia associated with NAFLD-NASH phenotypes, warranting further investigation in future studies. This evidence concerns the gene CRELD2 and metabolic dysfunction-associated steatohepatitis.